Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data
September 22, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), a biopharmaceutical company focused on the treatment of mental...
Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
September 07, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
Dr. Matthew Johnson will lead research to look at the science and efficacy of MYCO-001 for the treatment of smoking cessation and nicotine dependence DENVER, Sept. 07, 2021 (GLOBE NEWSWIRE) --...
Mydecine to Participate in Upcoming Conferences in September 2021
September 02, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a clinical-stage biopharmaceutical company aiming to...
Mydecine Innovations Group Announces Mailing of Management Information Circular and Provides Update on Spin-Out of U.S. Cannabis Assets
August 24, 2021 15:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), is pleased to announce that it has filed and mailed its management...
Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine
August 18, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) announces it has signed a five-year research agreement with Johns Hopkins University (JHU) School of...
Mydecine Reports Second Quarter 2021 Financial Results and Provides Business Update
August 16, 2021 16:55 ET
|
Mydecine Innovations Group Inc.
Groundbreaking Progress in Clinical Trial and Drug Discovery Programs Enhanced Technology Offering with Mindleap 2.0, its Digital Health Platform to Support the Adoption of Psychedelics into Mental...
Mydecine to Participate in Upcoming Investor Events in August 2021
July 28, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, July 28, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...
Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds
July 21, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, July 21, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to...
Mydecine Innovations Group Announces Launch of Mindleap Version 2.0
July 13, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
The digital health platform will provide the infrastructure to support the conscious and trustworthy adoption of psychedelics DENVER, July 13, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group...
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
June 24, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, June 24, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to...